Rivastigmine in frontotemporal dementia: An open-label study

Drugs and Aging

Volumn 21, Issue 14, 2004, Pages 931-937

  Moretti, Rita ^a   Torre, Paola ^a   Antonello, Rodolfo M ^a   Cattaruzza, Tatiana ^a   Cazzato, Giuseppe ^a   Bava, Antonio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLINESTERASE INHIBITOR; NEUROLEPTIC AGENT; RIVASTIGMINE; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FALLING; FEMALE; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; HUMAN; HYPOTENSION; ITALY; MALE; MINI MENTAL STATE EXAMINATION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PRIORITY JOURNAL; RATING SCALE; STATISTICAL ANALYSIS;

AGED; CAREGIVERS; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHENYLCARBAMATES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 10344262045     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421140-00003     Document Type: Article

References (28)

1. Miller BL. Pick's disease and frontotemporal dementias: clinical and biological overview. 53rd Annual Meeting of the American Academy of Neurology; 2001 May 6-11; Philadelphia, 2FC.005-123-134
2. Cummings JL. Frontotemporal dementias: an update. 52nd Annual Meeting of the American Academy of Neurology; 2000 Apr 30-May 5; San Diego, 2FC.002-72-94
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Association, 1994
4. Mendez MF, Selwood A, Mastri AR, et al. Pick's disease versus Alzheimer's disease: a comparison of clinical characteristics. Neurology 1993; 43: 289-92
5. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57: 416-8
6. Miller BL, Ikonte C, Ponton M, et al. A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single photon emission CT correlations. Neurology 1997; 48: 937-42
7. Duara R, Lopez-Alberoloa RF, Barker WW, et al. A comparison of familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1377-82
8. Levy ML, Miller BL, Cummings JL, et al. Alzheimer disease and frontotemporal dementias: behavioural distinctions. Arch Neurol 1996; 53: 687-90
9. Sjogren M. Clinical and physiopatholpgical aspects of FTD: oral communication. Alzheimer's disease vs other degenerative dementias: from biology to treatment. International Congress; 2000 Jun 16; Perugia
10. Rascovsky K, Salmon DP, Ho GJ, et al. Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD. Neurology 2002; 58: 1801-8
11. Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10 Suppl. 1: 80-4
12. Gallarda T, Olie JP. Biological therapies of behavioral and psychological symptoms of dementia: update and prospects [in French]. Encephale 2000; 26: 72-80
13. Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289: 210-6
14. Weinstock M. Selectivity of cholinesterase inhibition. CNS Drugs 1999; 12: 307-23
15. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002; 203-204: 141-6
16. Moretti R, Torre P, Antonello RM, et al. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study, Int J Clin Pract 2004 Apr; 58 (4): 346-53
17. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14
18. Alexopoulos GS, Abrams RC, Young RC, et al. Cornell scale for depression in dementia. Biol Psychiatry 1988; 23: 271-84
19. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 (S1): 9-15
20. Greene JG, Smith R, Gardiner M, et al. Measuring behavioural disturbance of elderly demented in patients in the community and its effects on relatives: a factor analytic study. Age Ageing 1982; 11: 121-6
21. Ott BR, Lafleche G, Whelihan WM, et al. Impaired awareness of deficits in Alzheimer's Disease. Alzheimer Dis Assoc Disord 1996; 10: 68-76
22. Folstein M, Folstein S, McHugh P. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
23. Manos PJ. The utility of the ten-point clock test as a screen for cognitive impairment in general hospital patients. Gen Hosp Psychiatry 1997; 8: 469-76
24. Gorham DR. The proverbs test: psychological test specialists. Missoula (MT): Montana University Press, 1956
25. Mendez MF, Ferryman KM, Miller BL, et al. Behavioral differences between frontotemporal dementia and Alzheimer's Disease: a comparison on the BEHAVE-AD rating scale. Int Psychogeriatr 1998; 10: 155-62
26. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996; 47: 876-83
27. Rainer M, Mucke HAM. Long-term cognitive benefits from galanthamine in Alzheimer's disease. Int J Geriatr Psychopharmacol 1998; 1: 197-201
28. Cummings JL. Pronto-temporal dementia and Alzheimer's therapy, oral communication. Dementia Forum; 2000 Sep 21-24; San Petersburg